1. SUPPORTING R&D IN LIFE SCIENCES DIAA ABDELRAHMAN d.abdelrahman@elsevier.com +201000 49080 27/10/2014

2. ELSEVIER R&D SOLUTIONS AN EXTENSIVE ARRAY OF INTEGRATED INFORMATION TOOLS

3. THE ELSEVIER LIFE SCIENCE SOLUTIONS (ELSS) PORTFOLIO AN INFORMATICS PORTFOLIO OF SOLUTIONS & SERVICES THAT WORK WELL TOGETHER TO IMPROVE R&D OUTCOMES  Workflow specific decision tools that support key use cases and research outcomes in Life Sciences  Working as a portfolio - Evolving from ‘point solutions’ to tools that work together to support integrated, cross- domain workflows  Using our capabilities to provide services that address ‘custom’ use cases, changing how organizations manage R&D data Text Mining & Data Integration

4. CONTEMPORARY CULTURE OF DRUG DISCOVERY Academic Labs collaborating with Pharma/Biotech

6. TRENDS AND CHALLENGES THE NEED FOR INFORMATION SOLUTIONS 6 Key Trends  Need for greater efficiency (time, cost)  Early ‘GO/NO GO’ decisions  Integrate vast & diverse data sets  ‘Real-time’ information sharing to accelerate R&D  Increasingly complex science  Solutions to address ‘- Omics’ data  Rise in pharmacovigilance & safety monitoring  More stringent regulatory requirements Falling R&D Productivity Greater Collaboration Need for Innovation Risk Management Common Challenges  Understand chemistry, targets, pathways & disease  Translate pre-clinical data into the clinic  Standardize & integrate data to extract actionable insights for sharing  Centralize information  Characterize and discover new targets / molecules to drive innovation  Aggregate, mine and analyze large, diverse data  Monitor and manage safety data to anticipate risk ELSS Solutions

7. ELSS PORTFOLIO Supporting innovation in drug discovery

8. Text Mining & Data Integration

10. Choosing one wrong target costs time(2½yrs) & money ($3.5M) and has more substantial repercussions ($254M and 13yrs lost) in the long term. Reducing the risk by increasing knowledge around targets from the start is pivotal in drug discovery. FINDING GOOD TARGETS REMAINS A CHALLENGE 30% of Phase II failures from 2008-2010 were related to validated targets “Large numbers of failures are occurring with drugs that have novel mechanisms of action in areas of high unmet medical need..”